Category:
FUNDING
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."
MMI Raises $110 Million in Series C Financing
MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
Tevogen Bio Announces $8 Million Equity Investment
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental Raises US$2.344bn Unitranche Debt Facility With KKR
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion Closes $57.7 Million in Series E Financing
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare Achieves More Than $7 Million in Funding for Commercial Expansion of First-In-Class Ear Imaging Technology
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.
Vicarious Surgical Raises An Additional $13.2 Mil in Capital
Vicarious Surgical added Philip Liang and Ric Fulop to their Board of Directors.
Nalu Medical Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
“Nalu Medical has made tremendous strides commercially and clinically in the past two years. Novo’s investment in Nalu reflects that progress and the confidence they share in the strong commercial potential for Nalu,” observed Geoff Pardo of Gilde Healthcare and Chairman of the Nalu Board.
Neurolief Announces Strategic Equity Investment by Sawai Group Holdings
Mitsuo Sawai, CEO of Sawai Group Holdings, highlighted their commitment to improving patient care and expanding treatment options for migraine and depression through the introduction of Relivion® for at-home treatment under doctor supervision.
Medical Device News Magazine
